Viatris (VTRS) Free Cash Flow (2019 - 2026)
Viatris' (VTRS) quarterly Free Cash Flow came in at $348.4 million in Q1 2026, down 29.32% year-on-year from $492.9 million in Q1 2025, and down 43.74% quarter-over-quarter from $619.3 million in Q4 2025.
Viatris (VTRS) Free Cash Flow (2019 - 2026) Analysis & Trends
Viatris' Free Cash Flow history runs 8 years deep, the most recent figure standing at $348.4 million for Q1 2026.
- On a quarterly basis, Free Cash Flow fell 29.32% year-over-year to $348.4 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 5.9% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 2.01% from the prior year.
- Free Cash Flow slipped to $348.4 million in Q1 2026 per VTRS's latest filing, from $619.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $1.1 billion in Q1 2022 and bottomed at $35.3 million in Q4 2022.
- The 5-year median for Free Cash Flow is $564.8 million (2024), against an average of $551.7 million.
- Across the five-year window, Free Cash Flow sank 89.16% in 2022 and jumped 1041.64% in 2023, its largest moves.
- Year by year, Free Cash Flow stood at $35.3 million in 2022, then soared by 1041.64% to $403.0 million in 2023, then dropped by 15.06% to $342.3 million in 2024, then jumped by 80.92% to $619.3 million in 2025, then slumped by 43.74% to $348.4 million in 2026.
- Per Business Quant, the three latest VTRS Free Cash Flow figures stand at $348.4 million (Q1 2026), $619.3 million (Q4 2025), and $658.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 348.40 Mn |
| Mar 31, 2026 | 348.40 Mn |
| Dec 31, 2025 | 619.30 Mn |
| Dec 31, 2025 | 619.30 Mn |
| Sep 30, 2025 | 658.10 Mn |
| Sep 30, 2025 | 658.10 Mn |
| Jun 30, 2025 | 166.80 Mn |
| Jun 30, 2025 | 166.80 Mn |
| Mar 31, 2025 | 492.90 Mn |
| Mar 31, 2025 | 492.90 Mn |
| Dec 31, 2024 | 342.30 Mn |
| Dec 31, 2024 | 342.30 Mn |
| Sep 30, 2024 | 749.50 Mn |
| Sep 30, 2024 | 749.50 Mn |
| Jun 30, 2024 | 320.30 Mn |
| Jun 30, 2024 | 320.30 Mn |
| Mar 31, 2024 | 564.80 Mn |
| Mar 31, 2024 | 564.80 Mn |
| Dec 31, 2023 | 403.00 Mn |
| Dec 31, 2023 | 403.00 Mn |